February 12, 2007 – Cytyc will pay $452 million to buy fellow women’s health diagnostics company, Adeza; Diversa will exchange $154.7 million worth of stock to acquire Celunol, a company developing cellulosic ethanol; Onyx gained 97% on positive results for cancer drug Nexavar for liver cancer; Adolor began a multi-dose Phase I trial of ADL5859 for inflammatory pain; Targeted Genetics reported positive results from an investigatory arthritis treatment; ARIAD sold a non-exclusive license for its cell-signaling regulation technology to CellNexus; and Cell Therapeutics will spin off a company to focus on follow-on biologics. The Centient Biotech 200™ fell 19 points to 4031, a drop of .48%. More details...
